Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial

A new study by researchers from the International Agency for Research on Cancer (IARC) shows that a new quadrivalent human papillomavirus (HPV) vaccine, which targets HPV types 6, 11, 16, and 18, is safe and effective in provoking an immune response against these HPV types. The study was published in the journal Lancet Oncology.

The researchers compared the efficacy and safety of the new quadrivalent HPV vaccine, given in two doses to girls and boys aged 9–14 years, with those of a comparable vaccine, given in three doses to women aged 15–26 years. The results showed that the new quadrivalent HPV vaccine was as effective and as safe for the younger population as the comparable vaccine.

Access to this new, effective vaccine could help meet the global demand for HPV vaccines and boost coverage for both girls and boys globally.

Sharma H, Parekh S, Pujari P, Shewale S, Desai S, Bhatla N, et al.
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial
Lancet Oncol, Published online 7 November 2023;
https://doi.org/10.1016/S1470-2045(23)00480-1

Read the article